Werewolf Therapeutics, Inc. (HOWL) Stock Price & Analysis

Werewolf Therapeutics, Inc. (HOWL) rose 2.38% to USD 0.97 as of September 8, 2026 at 06:20 UTC, according to Nexqual real-time market data.

HOWL last closed at USD 0.97; the session ranged USD 0.93–0.97 on volume of 489,800 shares. Market capitalization is —, with a 52-week range of USD 0.27–2.38 (NCM). Source: Nexqual, September 8, 2026 at 06:20 UTC.

Key Statistics (as of September 8, 2026 at 06:20 UTC)

Technical Analysis (HOWL)

Nexqual's technical model rates HOWL "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 06:20 UTC.

From Werewolf Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
• We have provided initial preclinical data for our proprietary INDUCER™ T cell engager molecules demonstrating that our PREDATOR masking technology silenced peripheral activity and prevented cytokine release.
• Once our molecules are cleaved within the tumor, the cytokine is released for either intratumoral target binding or rapid systemic clearance. 7 Table of Contents • Conditional Activation : Upon reaching the TME, INDUKINE molecules are activated via cleavage of our proprietary linkers by tumor-specific proteases which results in release of the cytokines in the tumor.
• Key features of WTX-124 include preservation of full IL-2 potency and function as observed in preclinical studies, high affinity blockade of IL2—IL2R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and conditional protease activation within the TME due to our proprietary linker.

Partnerships

• In June 2024, we executed a transfer agreement, or the Transfer Agreement, to assign our rights in a development agreement with a contract manufacturer of our interferon alpha INDUKINE molecule JZP898 to Jazz.
• We are currently seeking a strategic partnership for the further development of WTX-124.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:20 UTC. This page is informational and not investment advice.